SV2 PET Imaging With [11C]APP311
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorYale University
About this trial
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Eligibility criteria
Qualifiers
Willing and able to give voluntary written informed consent
Male and Female subjects, age 18 to 65 years, inclusive
Disqualifiers
MRI metal exclusions and claustrophobia.
Education completed is less than 12 years
Trial design
Treatments tested in this trial
- [11C]APP311
Treatment groups
250 Participants
are divided into 3 treatment groupsSponsors and collaborators
Yale University
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov